KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to -$25.3 billion.

  • Astrazeneca's Accounts Payables fell 1253.06% to -$25.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$25.3 billion, marking a year-over-year decrease of 1253.06%. This contributed to the annual value of -$25.3 billion for FY2025, which is 1253.06% down from last year.
  • Astrazeneca's Accounts Payables amounted to -$25.3 billion in Q4 2025, which was down 1253.06% from -$25.0 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Accounts Payables ranged from a high of $22.4 billion in Q4 2023 and a low of -$25.3 billion during Q4 2025
  • Its 5-year average for Accounts Payables is -$14.4 billion, with a median of -$19.5 billion in 2023.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 25640.95% in 2021, then crashed by 20040.67% in 2024.
  • Astrazeneca's Accounts Payables (Quarter) stood at $18.9 billion in 2021, then grew by 0.54% to $19.0 billion in 2022, then rose by 17.51% to $22.4 billion in 2023, then plummeted by 200.41% to -$22.5 billion in 2024, then dropped by 12.53% to -$25.3 billion in 2025.
  • Its Accounts Payables was -$25.3 billion in Q4 2025, compared to -$25.0 billion in Q3 2025 and -$24.0 billion in Q2 2025.